Compare Stocks → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACXPNASDAQ:AVTXNASDAQ:LABPNASDAQ:SNPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.03+0.5%$2.24$1.17▼$8.82$31.99M-1.79143,040 shs16,796 shsAVTXAvalo Therapeutics$10.85-5.6%$11.22$3.95▼$1,130.40$11.18M1.21485,538 shs57,381 shsLABPLandos Biopharma$22.33-0.1%$16.99$2.50▼$22.84$69.67M0.1419,996 shs10,749 shsSNPXSynaptogenix$4.57-3.0%$4.72$3.53▼$47.00$4.98M1.2546,262 shs28,909 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+4.12%-4.72%+4.66%-29.62%-39.16%AVTXAvalo Therapeutics-2.05%-25.34%-20.65%+145.51%-98.05%LABPLandos Biopharma+0.72%+0.49%+3.86%+321.09%+647.83%SNPXSynaptogenix+0.21%-1.05%-4.66%-3.93%-76.60%The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals1.6297 of 5 stars3.52.00.00.02.51.70.0AVTXAvalo Therapeutics0.6596 of 5 stars0.04.00.00.03.31.70.0LABPLandos Biopharma0.1371 of 5 stars1.03.00.00.00.60.80.6SNPXSynaptogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals3.00Buy$12.00491.13% UpsideAVTXAvalo Therapeutics2.50Moderate BuyN/AN/ALABPLandos Biopharma2.00Hold$20.42-8.55% DownsideSNPXSynaptogenixN/AN/AN/AN/ACurrent Analyst RatingsLatest AVTX, SNPX, LABP, and ACXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024AVTXAvalo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform4/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.423/19/2024ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.002/28/2024ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AAVTXAvalo Therapeutics$1.92M5.82N/AN/A$9.11 per share1.19LABPLandos Biopharma$18M3.87N/AN/A$10.20 per share2.19SNPXSynaptogenixN/AN/AN/AN/A$25.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$1.15N/AN/AN/AN/A-289.69%-185.19%5/15/2024 (Confirmed)AVTXAvalo Therapeutics-$31.54M-$616.67N/AN/AN/A-1,639.50%-1,439.87%-113.95%5/16/2024 (Estimated)LABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%8/14/2024 (Estimated)SNPXSynaptogenix-$6.04M-$26.25N/A∞N/AN/A-22.50%-18.10%5/20/2024 (Estimated)Latest AVTX, SNPX, LABP, and ACXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024N/AACXPAcurx Pharmaceuticals-$0.24N/A+$0.24N/AN/AN/A 3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/A3/15/2024Q4 2023ACXPAcurx Pharmaceuticals-$0.26-$0.38-$0.12-$0.38N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.532.53AVTXAvalo TherapeuticsN/A1.821.82LABPLandos BiopharmaN/A6.096.09SNPXSynaptogenixN/A7.147.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%AVTXAvalo Therapeutics87.06%LABPLandos Biopharma49.06%SNPXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals35.30%AVTXAvalo Therapeutics0.20%LABPLandos Biopharma1.30%SNPXSynaptogenix4.33%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals415.76 million10.20 millionOptionableAVTXAvalo Therapeutics191.03 million1.03 millionNot OptionableLABPLandos Biopharma193.12 million3.08 millionNot OptionableSNPXSynaptogenix51.09 million1.04 millionNot OptionableAVTX, SNPX, LABP, and ACXP HeadlinesSourceHeadlineSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discoveryprnewswire.com - May 7 at 9:00 AMSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingfinanznachrichten.de - April 24 at 5:25 PMSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingprnewswire.com - April 24 at 9:15 AMSynaptogenix announces reverse stock split to regain Nasdaq complianceuk.investing.com - April 5 at 8:47 AMWhat's Going On With Synaptogenix (SNPX) Stock?msn.com - April 4 at 5:46 PMSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listingfinance.yahoo.com - April 3 at 9:57 AMU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%msn.com - February 22 at 8:39 PMSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disordersfinance.yahoo.com - December 19 at 2:36 PMSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sfinance.yahoo.com - December 6 at 2:15 PMSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technologyfinance.yahoo.com - November 2 at 11:29 AMSynaptogenix Inc’s latest rating changes from various analystsknoxdaily.com - September 27 at 3:37 PMSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Diseasefinance.yahoo.com - September 26 at 12:59 PMBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Studyfinance.yahoo.com - September 7 at 10:07 AMSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosisprnewswire.com - July 19 at 9:02 AMSNPX price target predicted to rise nearly $14.00 in 12 monthsknoxdaily.com - July 14 at 2:37 PMShort Volatility Alert: Synaptogenix Incbenzinga.com - July 14 at 2:37 PMSynaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%benzinga.com - July 13 at 1:58 PMSynaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at Conferencemarketwatch.com - July 13 at 1:58 PMSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neurosciencefinance.yahoo.com - July 13 at 1:58 PMSNPX - Synaptogenix, Inc.finance.yahoo.com - June 24 at 6:33 PMSynaptogenix Provides Corporate Update and Outlines Potential Business Opportunitiesfinance.yahoo.com - March 7 at 10:14 AMSNPX.Oreuters.com - February 27 at 12:25 AMPeering Into Synaptogenix's Recent Short Interestmsn.com - December 20 at 12:40 PMSynaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate failsseekingalpha.com - December 16 at 1:26 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcurx PharmaceuticalsNASDAQ:ACXPAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Avalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.SynaptogenixNASDAQ:SNPXSynaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.